PRESS RELEASE : Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Reschedules Reporting of 1st Quarter 2021 and Provides Update for Annual General Meeting of Shareholders

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous 
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Reschedules Reporting of 1st Quarter 2021 and Provides Update for 
Annual General Meeting of Shareholders 
2021-05-31 / 18:00 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
 
Vivoryon Therapeutics Reschedules Reporting of 1^st Quarter 2021 and Provides Update for Annual General Meeting of 
Shareholders 
 
HALLE (SAALE) / MUNICH, GERMANY, May 31, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( 
Vivoryon) announced today that the publication of the 1^st quarter 2021 financial results, which had been scheduled for 
June 1, 2021, will be postponed until June 25, 2021. 
 
In accordance with the decree of May 27, 2021 on amending some expiry dates of legal provisions made in connection with 
the COVID-19 outbreak as published on May 31, 2021, the Temporary COVID-19 Justice and Safety Act (Tijdelijke wet 
COVID-19 Justitie en Veiligheid) (the COVID Act) has been extended. Therefore, the annual general meeting will be held 
on Monday, June 28, 2021, at 10:30 a.m. (CEST) as a virtual meeting via an audio webcast which will be available, along 
with all relevant documents, on the company's website at: https://www.vivoryon.com/ 
ordinary-general-meeting-of-shareholders-2021/. As there will be no physical meeting, it will not be possible to attend 
the meeting in person. 
 
### 
 
For more information, please contact: 
Vivoryon Therapeutics N.V. 
Dr. Manuela Bader, Director IR & Communication 
Tel: [phone] 
Email: [e-mail] 
Trophic Communications 
Gretchen Schweitzer / Valeria Fisher 
Tel: [phone] or [phone] 
Email: [e-mail] 
About Vivoryon Therapeutics N.V. 
With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles 
in disease initiation and progression, Vivoryon's scientific expertise has facilitated the creation of a discovery and 
development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel 
therapeutic in type 2 diabetes. In its current programs Vivoryon is advancing its lead product, varoglutamstat (PQ912), 
in Alzheimer's disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications. In 
addition, the company pursues a development program for Meprin protease inhibitors with potential therapeutic use in 
fibrotic diseases, cancer and acute kidney injury. www.vivoryon.com 
Forward Looking Statements 
Information set forth in this press release contains forward-looking statements, which involve a number of risks and 
uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics N.V. as 
of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject 
to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to 
differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or 
undertaking to release publicly any updates or revisions to any such statements to reflect any change in our 
expectations or any change in events, conditions or circumstances on which any such statement is based. 
=---------------------------------------------------------------------------------------------------------------------- 
2021-05-31 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Vivoryon Therapeutics N.V. 
              Weinbergweg 22 
              06120 Halle/Saale 
              Germany 
Phone:        [phone] 
Fax:          [phone] 
E-mail:       [e-mail] 
Internet:     www.vivoryon.com 
ISIN:         NL00150002Q7 
WKN:          A2QJV6 
Listed:       Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Amsterdam 
EQS News ID:  1202653 
 
End of News   DGAP News Service 
=------------ 

1202653 2021-05-31

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1202653&application_name=news

(END) Dow Jones Newswires

May 31, 2021 12:00 ET (16:00 GMT)